
    
      To explore the safety and efficacy of ABT-925 treatment at three different doses for 6 weeks
      compared with placebo in subjects with a diagnosis of acute exacerbation of schizophrenia or
      schizoaffective disorder according to DSM-IV-TR criteria (Diagnostic and Statistical Manual
      of Mental Disorders, Fourth Edition Text Revision).
    
  